IL6 and blood coagulation disease: The limitation of this study could be unmeasured confounders such as the use of steroid anti-inflammatory medicine (dose and duration) and tocilizumab (interleukin-6 inhibitors) which might have been taken by a few patients before measuring inflammatory and coagulation-disorder markers.